KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Boston Scientific (BSX) EBITDA Margin (2016 - 2025)

Boston Scientific's EBITDA Margin history spans 17 years, with the latest figure at 15.61% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 81.0% year-over-year to 15.61%; the TTM value through Dec 2025 reached 18.0%, up 245.0%, while the annual FY2025 figure was 18.0%, 246.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 15.61% at Boston Scientific, down from 20.69% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 20.69% in Q3 2025 and bottomed at 5.76% in Q4 2021.
  • The 5-year median for EBITDA Margin is 15.1% (2022), against an average of 14.68%.
  • The largest annual shift saw EBITDA Margin soared 2091bps in 2021 before it tumbled -223bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 5.76% in 2021, then surged by 115bps to 12.4% in 2022, then increased by 26bps to 15.68% in 2023, then decreased by -6bps to 14.8% in 2024, then grew by 5bps to 15.61% in 2025.
  • Per Business Quant, the three most recent readings for BSX's EBITDA Margin are 15.61% (Q4 2025), 20.69% (Q3 2025), and 16.18% (Q2 2025).